Recombinant monoclonal antibody to HER2/neu. This antibody intended for the prophylaxis and treatment of HER2-positive breast cancer.
Figure 1 SK-OV-3 invasion after incubation with chA21 for 24h(x400).
The invaded cells were counted on the underneath of ECM-coated Millicell membrane, chA21 (6μg/ml).
Gao, Y., Wu, Q., Wu, Z. S., Zhang, G. H., & Zhang, A. L. (2011). Effects of an engineered anti-HER2 antibody chA21 on invasion of human ovarian carcinoma cell in vitro. Chinese Journal of Cancer Research, 23(2), 147-152.
Figure 2 Growth inhibition on tumor xenografts by chA21.
ErbB2-positive expression on BT-474 and SKOV-3 tumor xenografts conWrmed by IHC method. Scale bar 500 μm.
Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.
Figure 3 Growth inhibition on tumor xenografts by chA21.
A dose-dependent response induced by chA21 on both BT-474 and SKOV-3 xenografts. chA21 was given i.v. twice a week for total 24 days at doses of 20, 30 and 40 mg/kg. *p < 0.01 compared with control. **p < 0.01 compared with 20 mg/kg chA21 group. Results are given as representative of two independent experiments.
Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.
Figure 4 Growth inhibition on tumor xenografts by chA21.
Dose-dependent down-regulation of ErbB2 receptor on both BT-474 and SKOV-3 xenografts by chA21. By the end of in vivo experiment, tumors were excised, lysed and subjected to western blots with specific antibodies against ErbB2 ECD (Ab-20) and GAPDH.
Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.
Figure 5 Increased number and activation of NK cells by chA21.
Nude mice bearing BT-474 xenografts were treated i.v. with indicated drug alone or combinations. At the end of in vivo experiment, the total numbers of NK cells (DX5+ CD3- cells) in peripheral blood and the percentages of NK cells in lymphocytes were determined by fow cytometry.
Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.
Figure 6 Increased number and activation of NK cells by chA21.
NK cells were evaluated for CD69 and NKG2D expression by fow cytometry. Histograms show CD69 and NKG2D expression on this cell subset, and mean fuorescence intensity (MFI) denotes expression level. Tra Trastuzumab, PTX Paclitaxel. Results were presented as the average ± SD. Similar results were obtained in mice bearing SKOV-3 xenografts.
Shen, G., Huang, H., Zhang, A., Zhao, T., Hu, S., Cheng, L., ... & Song, L. (2011). In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. Cancer immunology, immunotherapy, 60(3), 339-348.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B008(A) | Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] | IF, FC, FuncS | scFv-(D-Arg)9 |
IAB-B008(G) | Recombinant Anti-human ERBB2 Intrabody [+36 GFP] | WB, ICC, FuncS | scFv-(+36GFP) |
IAB-B008(T) | Recombinant Anti-human ERBB2 Intrabody [Tat] | ICC, Neut, FuncS | scFv-Tat |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-761 | Anti-ERBB2 Recombinant Antibody (Margetuximab) | IF, IP, Neut, FuncS, ELISA, FC, WB | IgG1 - kappa |
TAB-049CT-S(P) | Anti-Human HER2/neu Recombinant Antibody scFv Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
TAB-049CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (ChA21) | WB | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G022E | Anti-ERBB2 immunotoxin 4D5 (scFv)-PE | Cytotoxicity assay, Function study | |
AGTO-G022D | Anti-ERBB2 immunotoxin 4D5 (scFv)-DT | Cytotoxicity assay, Function study | |
AGTO-G022G | Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel | Cytotoxicity assay, Function study | |
AGTO-G022R | Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA | Cytotoxicity assay, Function study | |
AGTO-G022S | Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-085 | Human Anti-ERBB2 Recombinant Antibody (PFBL-085) | ELISA, WB, FuncS | Human Fab |
PFBZ-041 | Human Anti-ERBB2 Recombinant Antibody (clone bH1); Fab Fragment | WB, IF, FuncS | Human Fab |
PSBC-157 | Human Anti-ERBB2 Recombinant Antibody (clone F0178C1); scFv Fragment | Neut | Human scFv |
PSBC-158 | Human Anti-ERBB2 Recombinant Antibody (clone Pertuzumab, 2C4); scFv Fragment | IP, Neut | Human scFv |
HPAB-0021-YC-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (HPAB-0021-YC-F(E)) | ELISA, Neut, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PNBL-066 | Recombinant Anti-HER2 VHH Single Domain Antibody (Gr3) | SPR | Llama VHH |
PNBL-067 | Recombinant Anti-HER2 VHH Single Domain Antibody (Gr6) | SPR | Llama VHH |
PNBL-069 | Recombinant Anti-HER2 VHH Single Domain Antibody (huMAb4D5-5) | ELISA | Llama VHH |
HPAB-1026WJ | Recombinant Camelid Anti-ERBB2 Single Domain Antibody | ELISA | Camelid VHH |
HPAB-0725-YJ-VHH | Camelid Anti-ERBB2 Recombinant Single Domain Antibody (SR-87) | ELISA | Camelid VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0193CL-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-0193CL-F(E)) | ELISA, Cyt, Internalization | Human Fab |
TAB-0194CL-F(E) | Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-0194CL-F(E)) | ELISA, Cyt, Internalization | Human Fab |
TAB-056CT | Human Anti-ERBB2 Recombinant Antibody (TAB-056CT) | WB | Human IgG |
TAB-048CT-S(P) | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-048CT-S(P)) | ELISA, WB | Human scFv |
TAB-040CT-F(E) | Anti-Human HER2/neu Recombinant Antibody Fab Fragment (C6.5) | ELISA, WB | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-033CT | Human Anti-ERBB2 Recombinant Antibody (TAB-033CT) | ELISA, WB | Human IgG1, κ |
TAB-038CT | Human Anti-ERBB2 Recombinant Antibody (TAB-038CT) | FuncS, FC | Humanized IgG1 |
TAB-039CT | Anti-Human HER2/neu Recombinant Antibody (h1E11) | WB | Humanized antibody |
TAB-041CT | Human Anti-ERBB2 Recombinant Antibody (TAB-041CT) | SPR, ELISA, WB | Humanized antibody |
TAB-050CT | Anti-Human HER2/neu Recombinant Antibody (HuA21) | Inhib, Cty, IHC, WB, IF, FC, ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-024LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Mouse antibody |
Gly-039LC | Recombinant Anti-Human ERBB2 Antibody (Fab glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-117LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Humanized antibody |
Gly-118LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Mouse antibody |
Gly-145LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-146LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
Gly-147LC | Recombinant Anti-Human ERBB2 Antibody (Fc glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-177LC | Recombinant Anti-Human ERBB2 Antibody (Non-glycosylated) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0195MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0695MZ | Chicken Anti-ERBB2 Polyclonal IgY | WB | Chicken antibody |
BRD-0779MZ | Chicken Anti-ErbB2 Polyclonal IgY | ICC, IF, IHC, IP | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-737CQ | Mouse Anti-ERBB2 Recombinant Antibody (clone 7.16.4) | Block, IP, IF, FC | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1178 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone DS1178AB) | IHC-P, IHC-Fr | Rabbit IgG |
MOR-4586 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH99DS) | WB | Rabbit IgG |
MOR-4587 | Hi-Affi™ Rabbit Anti-ERBB2 Recombinant Antibody (clone TH100DS) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-014LC | Mouse Anti-ERBB2 Recombinant Antibody (MOB-014LC) | ELISA, FC | Mouse IgG |
MOB-014LC-F(E) | Mouse Anti-ERBB2 Recombinant Antibody; Fab Fragment (MOB-014LC-F(E)) | ELISA, FC | Mouse Fab |
MOB-014LC-S(P) | Mouse Anti-ERBB2 Recombinant Antibody; scFv Fragment (MOB-014LC-S(P)) | ELISA, FC | Mouse scFv |
HPAB-0010-FY | Human Anti-ERBB2 Recombinant Antibody (HPAB-0010-FY) | ELISA, FC, ADCC | Human IgG1, κ |
HPAB-0011-FY | Mouse Anti-ERBB2 Recombinant Antibody (HPAB-0011-FY) | Inhib, ADCC, FuncS | Mouse IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-468CQ | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Timigutuzumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, FuncS | ADCC enhanced antibody |
AFC-TAB-053 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-761 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Margetuximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-005 | Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Trastuzumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0679YY-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone H2-18); scFv Fragment | ELISA | Human scFv |
FAMAB-0172JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6H2); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0173JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone C6H211); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0359JF-S(P) | Human Anti-ERBB2 Recombinant Antibody (clone FRc13); scFv Fragment | DB, ELISA, FuncS | Human scFv |
PSBS-0070 | Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (PSBS-0070) | ELISA, FuncS | Human scFv |
There are currently no Customer reviews or questions for TAB-049CT. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.